Metabolic stability plays an important role in the success of drug candidates. First-pass metabolism is one of the major causes of poor oral bioavailability and short half-life. Traditionally, metabolic stability was evaluated at a later stage of drug discovery and required laborious manual manipulations. With the advance of high-throughput screening, combinatorial chemistry, and early profiling of drug-like properties, automated and rapid stability assays are needed to meet the increasing demand of throughput, speed, and reproducibility at earlier stages of drug discovery. The authors describe optimization of a simple, robust, high-throughput microsomal stability assay developed in a 96-well format. The assay consists of 2 automated components: robotic sample preparation for incubation and cleanup and rapid liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) analysis to determine percent remaining of the parent compound. The reagent solutions and procedural steps were optimized for automation. Variables affecting assay results were investigated. The variability introduced by microsome preparations from different sources (various vendors and batches) was studied and indicates the need for careful control. Quality control and normalization of the stability results are critical when applying the screening data, generated at different times or research sites, to discovery projects. (Journal of Biomolecular Screening 2003:453-462) 
INTRODUCTION
I n today's drug discovery research, drug candidates not only have to be potent, selective, and safe but also must possess druglike properties to increase the success rate to the clinic. Early screening of pharmaceutical properties provides valuable and timely information for discovery teams to optimize drug-like properties in parallel with the activity optimization. Several reviews have discussed in vitro property screening assays. [1] [2] [3] [4] [5] Among the critical properties, metabolic stability plays an important role in oral bioavailability and overall pharmacokinetic performance. Typically, liver microsomes are used to screen the primary form of metabolic instability resulting from phase I oxidation. Rapid screening of microsomal stability in drug discovery alerts research teams to potential liabilities of the compounds and provides useful information to develop structure-metabolic stability relationships. Synthetic strategies can then be planned to overcome the hurdle of rapid metabolism.
High-throughput methods for microsomal stability [6] [7] [8] [9] must incorporate 2 automation procedures for (1) microsomal incubation, sample preparation, and cleanup and (2) rapid quantitation with liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) for large numbers of samples. In our laboratory, we developed a high-throughput integrated LC/MS/MS system suitable for screening purposes 10 that is based on commercially available instrumentation and software, easy to set up and maintain, robust, reproducible, and rapid. In this article, we discuss method development of an automated procedure for microsomal incubation, sample preparation, and cleanup, as well as enhancement of the automated instrumental LC/MS/MS method for microsomal stability screening. The various conditions of the assay that are critical to accurate and reliable performance were investigated. These include effects of substrate concentration, percent DMSO, and batch-to-batch and vendor-to-vendor variability of microsomes. As organizations implement higher throughput property screening assays, the detailed assay conditions, automation proce-dures, and precautions discussed here will be useful for rapid setup and production of quality data.
MATERIALS AND METHODS

Chemicals
All reagents used were of the highest grade commercially available. Loperamide, buspirone, midazolam, propranolol, warfarin, despiramine, and thioridazine were obtained from Sigma Chemical Co. (St. Louis, MO). Imipramine (ICH Biomedicals, Inc., Aurora, OH), NADPH-regenerating agent solution A and solution B (BD Gentest, Woburn, MA), 0.5 M EDTA (GIBCO, Grand Island, NY), male Sprague-Dawley rat liver microsomes (In Vitro Technologies, Baltimore, MD; BD Gentest, Woburn, MA; CEDRA Corporation, Austin, TX), male CD1 mouse liver microsomes (In Vitro Technologies, Baltimore, MD), and Supermix human P450 (BD Gentest, Woburn, MA) were purchased from the sources indicated.
Instrumentation
A Packard Multiprobe II HT EX robot with 8 probes was used for liquid handling (PerkinElmer, Downers Grove, IL). Model 1100 high-performance liquid chromatography (HPLC) pumps (Agilent Technology, Piscataway, NJ) were used. A CTC Twin Pal autosampler (LEAP Technologies, Carrboro, NC) equipped with 6 cooled well plate holder drawers (12-tray capacity), a syringe injection valve, and a 10-port valve to which 2 trapping cartridges were attached was used. A triple quadrupole Micromass Quattro Micro mass spectrometer (Waters, Milford, MA), with either electrospray (ESI) or atmospheric pressure chemical ionization (APCI), was used for sample analysis.
Preparation of optimization plate, sample plate, cofactor, and microsomes
An optimization plate (25 µM of test compound in 2:1 acetonitrile [ACN]/100 mM phosphate buffer, pH 7.4, in a 1-mL 96-deep well plate, Corning Incorporated, Corning, NY), used for automated development of unique tandem mass spectrometer multiple-reaction monitoring (MRM) quantitation conditions for analysis of each compound, was prepared using the Packard robot by diluting a 1-mg/mL DMSO stock solution of each compound. The robotic software and formula weight were used to automate the process of calculating the volume of 2:1 ACN/buffer and DMSO stock for each compound and mixing to obtain the 25-µM solution.
A sample stock plate of test compounds (100 µL of 0.5 mM in DMSO) in a 96-shallow well plate (Corning Incorporated, Corning, NY) was prepared using the Packard robot by diluting a 1-mg/mL DMSO stock solution of each compound. The robotic software and formula weight were used to automate the process of calculating the volume of DMSO and DMSO stock for each compound and mixing to obtain the 0.5-mM solution.
Dilution buffer was prepared in bulk and contained 5 mM EDTA in 100 mM potassium phosphate buffer at pH 7.4.
A batch of 100-mM phosphate buffer tubes was prepared ahead of time using the robot and stored in the refrigerator (-4°C) for later use. Each of these contained 10.938 mL of 100 mM phosphate buffer at pH 7.4.
NADPH cofactor solution was prepared before incubation. To each of the 2 tubes containing 10.938 mL of phosphate buffer (see above paragraph for preparation), 1.609 mL of NADPH-regenerating solution A and 0.322 mL of NADPH-regenerating solution B were added. The tubes were mixed and placed in a trough on the robot deck, labeled cofactor in Figure 1 .
Microsomes were prepared as follows. The protein concentration of this microsome preparation was 1.25 mg/mL. For a microsome batch with an initial concentration of 27 mg/mL, 0.531 mL of microsomes was added to each of 2 phosphate buffer tubes (above) that were prewarmed at 37°C for at least 10 min (just prior to the step when microsomes were added for incubation, as described below). The tubes were mixed and placed into a trough on the robot deck, labeled microsomes in Figure 1 .
Preparation of incubation plates
All reagents and plates were placed on the robotic deck according to Figure 1 . This includes the following: the dilution buffer (100 mL in 150-mL trough, PerkinElmer, Downers Grove, IL), NADPH cofactor (13 mL in 25-mL trough, PerkinElmer), sample stock plate (100 µL, 0.5 mM in DMSO), dilution plate (empty 2-mL 96 deep well, Matrix Technologies Corp., Hudson, NH), incubation plate (empty 1-mL 96 deep well, Corning Incorporated), and transfer plate (empty 1-mL 96 deep well). Prewarmed microsomes (see previous section) and cold ACN stop solution (4°C) were placed in their respective troughs (microsomes in 25-mL trough and ACN in 150-mL trough) on the deck right before being added by the robot to the incubation plate. The starting and final concentrations of the reagents are summarized in Table 1 .
For the time 5 (min) incubation plate, the robot performed the preparation of the incubation plate as follows:
1. 990 µL of dilution buffer was added to each well of the 2-mL deep well dilution plate; 2. 10 µL of sample stock (0.5 mM) was added to the corresponding well of the dilution plate and mixed by aspiration/dispensation 3 times at high speed to form the diluted sample; 3. 100 µL of NADPH cofactor (see previous section) was added to each well of the incubation plate; 4. 50 µL of each diluted sample was added to the 1-mL deep well incubation plate in duplicate and warmed at 37°C for 10 min; 5. 100 µL of the prewarmed microsomes (see previous section) was added to each well of the incubation plate; 6. the plate was incubated off the robot at 37°C, 70 rpm for 5 min on a shaker (Armalab, Bethesda, MD); 7. at the end of the incubation, the plate was immediately returned to the Packard robot, and 500 µL of cold acetonitrile was added to each well. The plate was gently mixed on a vortexer (VWR, So. Plainfield, NJ).
For the time 0 (control) plate, the robot performed all the preparation of the incubation plate as follows:
1. a new incubation plate was placed on the robot; 2. 100 µL of the prewarmed microsomes was added to each well of the reaction plate; 3. 50 µL of each diluted sample was added to the 1-mL deep well reaction plate in duplicate, and the plate was mixed; 4. 500 µL of cold acetonitrile was added to each well; 5. 100 µL of NADPH cofactor was added to each well, and the plate was mixed/vortexed. Preparation of both plates (time 0 control and time 5) for quantitation was as follows:
1. centrifuge at 3000 rpm at 10°C for 15 min; 2. 500 µL of the supernatant was transferred by the robot to the transfer plate for LC/MS/MS analysis.
LC/MS/MS analysis
Method development studies for the high-throughput LC/MS/ MS system were previously described. 10 The configuration is shown in Figure 2 . The method was enhanced for this microsomal stability assay by using a trapping cartridge (see below) that improved trapping efficiency and peak shape and reduced cost. The MS method for each compound was developed for MRM conditions (ESI+, ESI-, cone voltage, and collision energy) with Quan_Optimize software using the optimization plate. The MRM methods for each compound were automatically created and ready to be used for analysis. HPLC pump and washed for 5 sec, and then the trapped components were eluted with 0.1% formic acid/(95% acetonitrile/water) at 1 mL/min in reversed flow for 0.5 min. Because there were 2 trapping cartridges attached to the 10-port valve, a sample was being loaded onto 1 cartridge while the sample was being eluted from the other cartridge in an alternating load-and-elute sequence. No analytical HPLC column was used because the selectivity of the MS/MS system is sufficient for screening purposes. Total analysis time was 1.2 min/injection. The details of the instrumental conditions are listed in Table 2 .
Generic high-throughput LC/MS/MS method
The peak area of the parent compound in the time 5 sample was divided by the area of the time 0 (control) and multiplied by 100 to calculate the percent remaining after incubation. This value was used as an estimate of the microsomal stability of the test compounds.
Backup generic LC/MS method
Compounds that failed development of MRM conditions using ESI and Quan_Optimize were analyzed with backup conditions in-volving LC/MS with APCI. Then, 20 µL of the time 0 or time 5 samples was injected onto an analytical column (Aquasil C18, 2.1 × 50 mm, 5 µm, Keystone Scientific, Bellefonte, PA) and detected with APCI using selected ion monitoring (SIM). Either APCI+ or APCI-ion was used, depending on whether the compound contained a basic or acidic group, respectively. Percent remaining was calculated as for the generic ESI analysis method. The details of the instrumental conditions are listed in Table 2 .
Effects of substrate concentration and animal species
The effect of substrate concentration on percent remaining results was investigated at 0.5, 1, 2, 5, 10, and 15 µM for 3 animal species (rat, mouse, and human Supermix). Eight commercial drugs (loperamide, buspirone, midazolam, propranolol, warfarin, imipramine, despiramine, and thioridazine), having a range of metabolic stabilities, were used for the study. Stock solutions of these drugs, with concentrations of 0.25 mM to 7.5 mM in DMSO, and microsomal protein at 0.5 mg/mL concentration were used. The robotic protocols for sample incubation, preparation, and LC/ MS/MS quantitation, described above, were applied for this study.
Effect of percent DMSO
The effect of DMSO concentration on percent remaining results was investigated with 1%, 0.5%, and 0.2% DMSO (% v/v) at 1 µM substrate concentration for 6 commercial drugs (loperamide, buspirone, midazolam, propranolol, warfarin, and imipramine) in rat liver microsomes. The 1% DMSO sample was prepared by removing 40 µL of aqueous buffer from a well of the dilution plate (described above) and adding 40 µL of DMSO prior to adding the stocks of the commercial drugs. The 0.5% DMSO sample was prepared by removing 10 µL of aqueous buffer and adding 10 µL of DMSO prior to adding the stocks of the commercial drugs. The 0.2% DMSO sample had no buffer removed. Otherwise, the ro- botic protocols for sample incubation, preparation, and LC/MS/ MS quantitation, described above, were applied for this study.
Effect of variation of liver microsome preparation
The effect of variations in liver microsome preparation was examined with 3 commercial drugs (midazolam, buspirone, and loperamide). Rat liver microsomes from 3 different vendors and 3 batches from the first vendor were used in the assay at 1 mg/mL protein concentration and a 30-min incubation time. The robotic protocols for sample incubation, preparation, and LC/MS/MS quantitation, described above, were applied for this study.
RESULTS
General assay considerations
The liquid-handling robot was used successfully for both reagent preparation, addition of reagents, and sample preparation. The flexibility of modern laboratory robots allows the programming of multiple procedures and deck layouts, with rapid transition between tasks.
Initial studies indicated that the viscous nature of the microsomal preparation caused pipetting of the material to be imprecise. Premixing with phosphate buffer reduced the viscosity and increased reproducibility.
Use of the commercially available NADPH-regenerating reagents improved the reproducibility and reliability of the reagent. It also reduced the time required for weighing and dilution of each reagent component.
The precision of the method increased when it was transferred from manual liquid reagent addition to robotic liquid handling. Robotics also reduced the tedium of manual reagent liquid handling and greatly increased the productivity of the scientist performing the work. Although the method does not have throughput as high as high-throughput screening (HTS), it is much higher throughput than is commonly found in metabolic stability assays.
Use of Quan_Optimize software automated the MRM method development process. In typical manual operations, each compound for MRM analysis is infused into the mass spectrometer, and conditions are developed manually by a trained analyst. This is prohibitive if 50 to 250 compounds per day are scheduled to be quantitated. Thus, the vendor software worked quite well to automate a normally time-consuming process. This capability increases the opportunity to use mass spectrometry as a selective tool for higher throughput screening analysis. The specificity provided by MS/MS MRM analysis reduces the need for an analytical HPLC column and the time-consuming chromatographic separation for each sample injection.
Effects of substrate concentration and animal species
The microsomal stability of loperamide, buspirone, midazolam, propanolol, warfarin, imipramine, despiramine, and thioridazine was studied at substrate concentrations from 0.5 µM to 15 µM compound concentration for 3 different species (rat, mouse, and human CYP450 Supermix). The results (Fig. 3) indicate that substrate concentration dramatically affects assay results, and the effect is compound dependent. In the case of propanolol in rat liver microsomes, the percent remaining is 76-fold higher at 10 µM than at 1 µM (76% remaining vs. 1%). This indicates a saturation effect. In the case of warfarin, the results are similar at all the concentrations. The data indicate that sample concentration should be kept low, and 1 µM was selected as the concentration for the assay. Data revealed species differences in stability. The test compounds tend to be least stable in rat liver microsomes. The assay can be easily adapted to liver microsomes from different species by simply changing the microsomes added.
Effect of percent DMSO
The effect of percent DMSO on percent remaining is summarized in Figure 4 . Percent DMSO was studied at 1%, 0.5%, and 0.2% at 1 µM substrate concentration in rat liver microsomes. The results show that higher DMSO concentration gives artificially higher percent remaining results. The effect of percent DMSO on assay results is compound dependent. The DMSO effect is more pronounced for some compounds than for others. In the case of buspirone, a 10% difference in percent remaining (from 12% remaining at 0.2% DMSO to 22% remaining at 1% DMSO) was observed when percent DMSO was increased from 0.2% to 1%. The data indicate that percent DMSO should be kept low and 0.2% DMSO is preferred, but general metabolic trends can still be observed at 1% DMSO.
Variation of rat liver microsomes
Comparison of rat microsomal activities from 3 vendors and 3 batches from the first vendor is shown in Figures 5 and 6 . The results varied significantly, and the variation is substrate dependent. Microsomes from the last vendor show no metabolic activity on buspirone and loperamide. The last 2 batches from the first vendor are much more active than the first batch.
Assay throughput, speed, and reproducibility
The automation scheme for the high-throughput microsomal stability assay is shown in Figure 7 . The total sample incubation and preparation time was about 1.5 h/plate of 48 samples in duplicate (96 wells). This reduced the sample preparation time to onehalf of the manual preparation time (3 h). Furthermore, the automated assay required minimal human intervention, which significantly saved the operator's time, reduced error, and increased efficiency. The analysis time for high-throughput (HT) LC/MS/MS was 2 h/plate of 48 samples in duplicate (96 wells, 1.2 min/ injection). HT LC/MS/MS analyses were run unattended overnight. A typical chromatogram is shown in Figure 8 . Under optimal conditions, the throughput of the assay is 1200 samples/week Substrate dards for day-to-day variation are shown in Figure 9 . The average variance for percent remaining of duplicate samples is 4.9% for a study of 30 Wyeth Research compounds. Percent coefficient of variation (%CV) for manual operation was around 30%. These data indicate that the assay is robust and reproducible, and the %CV is much improved as compared to manual preparation.
DISCUSSION
High-throughput microsomal stability assays are used to profile drug discovery candidates to alert discovery teams to potential metabolic liabilities and to guide synthetic modification for opti-mal in vivo performance. Incubation assay conditions appear as though they should be straightforward, but assay conditions and variation in reagents can dramatically affect test results, which might lead to erroneous conclusions. A wide range of microsomal assay conditions has been reported in the literature. The lack of standard conditions and consistency among laboratories led us to undertake the method development project described here.
The result of these method development studies has been the simple, robust, and high-throughput microsomal stability assay with rapid LC/MS/MS analysis described here. Various assay conditions were explored for optimal results. The concentration of the test compound reported in the literature for microsomal stability assays varies from 0.5 to 15 µM. 4, [6] [7] [8] [11] [12] [13] Microsomal stability, based on percent remaining of parent, is dependent on the test concentration due to nonlinear kinetics. Higher test concentrations (e.g., 10 µM) produce results indicating apparently higher stability. In drug discovery, with single-concentration screening, it is recom- mended to use consistent substrate concentration so that the results will be comparable for ranking compounds. It has been proposed that when compounds are incubated at a low concentration (≤ 1 µM), assuming a first-order process ([S] < K m ), the disappearance of the parent compound can be used to determine intrinsic clearance. 11, 12 Incubation at 1 µM will give a final concentration of 0.3 µM after acetonitrile precipitation. This is sufficient for LC/MS/ MS analysis using SIM or MRM conditions. An important reason to use low substrate concentration is poor aqueous solubility of many test compounds. Some compounds may precipitate at substrate concentrations of 10 µM. The solid material will be solubilized by acetonitrile at the end of the incubation and result in an artificially higher percentage remaining. DMSO is the most common solvent used to dissolve compounds for activity and property screening in drug discovery. DMSO was reported to inhibit enzyme activities of several cytochrome P450s by 15% to 25% even at a low percentage, especially for CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP2E1. 14, 15 We found that the activity of rat liver microsomes is sensitive to even a low percentage of DMSO. Because the inhibitory effect of DMSO is different for each compound, it is important to use a low percentage of DMSO (e.g., 0.2%) in the microsomal screening assay to minimize the solvent inhibition effects.
In drug discovery, it is very convenient for screening assays to use frozen liver microsomes because they are readily available commercially and can be stored frozen at -80°C for at least 2 years. 12 However, the activity of the commercial microsomes varied significantly from batch to batch and from vendor to vendor due to inherent animal-to-animal variation and differences in preparation protocol. In drug discovery, microsomal stability data are used to rank compounds for all discovery projects over an extended period of time. Variations in data due to microsomal batch variation will make it difficult to use the data. It is a good practice to QC new batches of microsomes and adjust incubation conditions (e.g., incubation time) accordingly and to normalize the assay results, so that comparisons can be made on data generated from different batches of microsomes over an extended period of time. Other alternative approaches to reduce variation of microsomes and to increase the robustness of the assay include (1) in-house preparation of microsomes and (2) purchasing a large batch of microsomes from a vendor.
CONCLUSIONS
A simple, robust, and high-throughput microsomal stability assay method has been developed. Assay conditions dramatically affect test results. Careful design and validation of high-throughput assays are recommended to ensure quality data and reliable predictions. Important sources of variation are substrate concentration, percent DMSO, and microsomal activity from batch to batch and from vendor to vendor. The assay is comparable with a validated standard metabolic stability method used in lead optimization, in which multiple time points were investigated.
This assay is being used in conjunction with other pharmaceutical profiling assays to rank compounds and maximize the drug-like properties for discovery candidates. Structure-metabolic stability relationships are developed to improve metabolic profiles. Compounds with poor stability are evaluated with secondary assays, such as stability at different time points, different animal species, liquid chromatography/nuclear magnetic resonance, and LC/MS/ MS for metabolite identification.
